← Back to Clinical Trials
Recruiting Phase 2 NCT06509334

Trial of JYB1904 in Chronic Spontaneous Urticaria.

Trial Parameters

Condition Chronic Spontaneous Urticaria
Sponsor Jemincare
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 135
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-08-04
Completion 2026-07-15
Interventions
JYB1904JYB1904Omalizumab

Brief Summary

This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.

Eligibility Criteria

Inclusion Criteria: * Male or female adult subjects (≥18 years of age). * Diagnosis of Chronic Spontaneous Urticaria(CSU) ≥ 3 months prior to Screening Visit 1 and previously inadequately controlled with a second-generation H1 antihistamine. * Itching and hives lasting ≥ 6 weeks prior to Screening Visit 1. * Have a UAS7 (range 0 - 42) ≥ 16, an ISS7 (range 0 - 21) ≥ 6, and an HSS7 (range 0 - 21) ≥ 6 within 7 days prior to randomization. Exclusion Criteria: * Induced urticaria with a defined trigger, including artificial urticaria (cutaneous scratches), cold-contact, heat-contact, solar, pressure, delayed-pressure, water-source, cholinergic, or contact urticaria * Any other dermatological condition with chronic itching, such as atopic dermatitis, herpetic pemphigoid, herpetic dermatitis, senile itching, or psoriasis, which in the opinion of the investigator may affect the study assessment and study results * Other conditions with symptoms of urticaria or angioedema, including but not lim

Related Trials